Clinical Core

项目摘要-临床核心(核心B) 威斯康星州阿尔茨海默病研究中心(ADRC)临床核心的主要目标是 为调查人员提供具有良好特征的、多样化的患者和对照人群以及高质量、 标准化的临床、认知、脑脊液、血清/血浆、DNA和神经影像数据 促进转化性阿尔茨海默病(AD)的临床前诊断和早期干预研究。到那时候 CORE对轻度认知障碍(MCI)患者进行全面的临床评估 AD引起的轻度痴呆、认知正常的老年对照组(OCN，&>65岁)和中年人(Impact 年龄在45-65岁之间)，根据家族病史有不同程度的痴呆症风险。临床核心团队工作 与所有核心部门密切合作，通过参加外联和招聘活动促进中心的使命 多样化的社区；对核心参与者进行标准化的临床和认知评估；收集 与衰老相关的辅助认知和临床数据，包括详细的血管风险评估；收集高风险 高质量的血液、脑脊液和DNA生物样品；协调生物样品采集和神经成像；完成 及时进行标准化数据报告；为获得诱导多能性进行皮肤活检 干细胞(IPSC)系；同意核心参与者进行脑部尸检；促进认知测试和脑脊液 在研究人员发起的研究中收集数据；并确保参与者、数据和 向当地和其他地区的研究人员提供生物武器。在下一个赠款周期中，核心将完成以下工作 目标：目标1：继续招募和留住认知正常的成年人(IMPACT和OCN)和患者 使用MCI进行详细的年度(MCI、OCN)或两年一次(影响)临床评估(包括标准化 统一数据集[UDS]数据和血液样本)以及两年期(MRI、脑脊液)和基线(子集中的PET) 支持临床前痴呆的转译研究的生物标记物评估。目标2：继续招募和 保留AD导致的轻度痴呆患者进行详细的年度临床和血液生物标记物评估 (包括标准化的UDS数据)和可选的附加基线生物标记物评估(MRI、CSF、PET)。 目标3：继续将文化定制的外展、教育和临床服务整合到不同的 社区提高对大脑健康的认识并鼓励长期参与研究(包括 临床和生物标记物评估)和在代表性不足的少数族裔社区进行宣传。目标4：继续 获得同意捐献大脑以支持临床病理研究并收集脑脊液、血液、DNA和 用于MCI和AD痴呆临床前标志物翻译研究的IPSCs。目标5：继续提供 基础设施、资源和服务，以促进正常认知老化、临床前的协作研究 痴呆症和阿尔茨海默病所致的痴呆症，并加快与国家阿尔茨海默氏症患者共享数据和资源 协调中心、国家阿尔茨海默病细胞库和其他AD中心和调查人员。

PROJECT SUMMARY - CLINICAL CORE (CORE B) The primary objective of the Wisconsin Alzheimer's Disease Research Center's (ADRC) Clinical Core is to provide investigators access to well-characterized, diverse patient and control populations and high-quality, standardized clinical, cognitive, cerebrospinal fluid (CSF), serum/plasma, DNA, and neuroimaging data to facilitate translational Alzheimer's disease (AD) research in preclinical diagnosis and early intervention. To that end, the Core conducts comprehensive clinical evaluations in patients with mild cognitive impairment (MCI) and mild dementia due to AD, cognitively normal older controls (OCN, >65 years), and middle-aged adults (IMPACT cohort, 45-65 years) with varying levels of dementia risk based on family history. The Clinical Core team works closely with all Cores to facilitate the Center's mission by participating in outreach and recruitment activities to diverse communities; conducting standardized clinical and cognitive assessments of Core participants; gathering ancillary aging-related cognitive and clinical data, including a detailed vascular risk assessment; collecting high- quality blood, CSF, and DNA biospecimens; coordinating biospecimen collection with neuroimaging; completing standardized data reporting in a timely manner; conducting skin biopsies for acquisition of induced pluripotent stem cell (iPSC) lines; consenting Core participants for brain autopsy; facilitating cognitive testing and CSF collection within investigator-initiated studies; and ensuring timely availability of participants, data, and biospecimens to researchers locally and beyond. In the next grant cycle, the Core will accomplish the following aims: Aim 1: Continue to recruit and retain cognitively unimpaired adults (IMPACT and OCN) and patients with MCI for detailed annual (MCI, OCN) or biennial (IMPACT) clinical assessments (including standardized Uniform Data Set [UDS] data and blood samples) and for biennial (MRI, CSF) and baseline (PET in subset) biomarker assessments to support translational research in preclinical dementia. Aim 2: Continue to recruit and retain patients with mild dementia due to AD for detailed annual clinical and blood biomarker assessments (including standardized UDS data) and optional additional baseline biomarker assessments (MRI, CSF, PET). Aim 3: Continue to integrate culturally-tailored outreach, education, and clinical services to diverse communities to raise awareness of brain health and encourage long-term research engagement (including clinical and biomarker assessments) and advocacy in underrepresented minority communities. Aim 4: Continue to obtain consents for brain donation to support clinical-pathologic research and collect CSF, blood, DNA, and iPSCs for translational research on preclinical markers of MCI and AD dementia. Aim 5: Continue to provide infrastructure, resources, and services to facilitate collaborative research in normal cognitive aging, preclinical dementia, and dementia due to AD and expedite sharing of data and resources with the National Alzheimer's Coordinating Center, National Cell Repository for Alzheimer's Disease, and other AD Centers and investigators.